Список литературы

Поставить закладку

Miller R.W., Young J.L., Novakovic B. Childhood cancer // Cancer. John Wiley & Sons, Ltd, 1995. Vol. 75, № S1. P. 395-405.
Pastore G., Peris-Bonet R., Carli M., Martínez-García C., de Toledo J. S., Steliarova-Foucher E. Childhood soft tissue sarcomas incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System project. European Journal of Cancer. 2006; 42(13), 2136-2149. https://doi.org/10.1016/j.ejca.2006.05.016
Doyle L.A. Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone // Cancer. John Wiley and Sons Inc., 2014. Vol. 120, № 12. P. 1763-1774.
Stiller C.A., Parkint D.M. International variations in the incidence of childhood soft‐tissue sarcomas // Paediatr. Perinat. Epidemiol. Paediatr Perinat Epidemiol, 1994. Vol. 8, № 1. P. 107-119.
Weihkopf T. et al. Incidence and time trends of soft tissue sarcomas in German children 1985-2004 - A report from the population-based German Childhood Cancer Registry // Eur. J. Cancer. Eur J Cancer, 2008. Vol. 44, № 3. P. 432-440.
Gurney J.G., Young J.L., Roffers S.D. Soft tissue sarcomas // Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. 1999. P. 111-124.
Koscielniak E., Klingebiel T. CWS-guidance for risk adapted treatment of soft tissue sarcoma (STS) and soft tissue tumours in children, adolescents, and young adults. https://fnkc.ru/fnkc/docs/CWS-2009.pdf
Kallen M.E. et al. The 2020 WHO classification. Whats new in soft tissue pathology? Am J Surg Pathol 2020;
Sbaraglia M. et al. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. PATHOLOGICA 2021;113:70-84
Детская онкология. Национальное руководство. Под ред. М.Д. Алиева, В.Г. Полякова, Г.Л. Менткевича, С.А. Маяковой. М.: Издательская группа РОНЦ. Практическая медицина, 2012. 684 p.
Schiavetti A. et al. Long-term renal function and hypertension in adult survivors of childhood sarcoma: Single center experience // Pediatric Hematology and Oncology. Taylor and Francis Ltd, 2018. Vol. 35, № 3. P. 167-176.
Brecelj J., Stirn-Kranjc B., krbec M. Visual electrophysiology in children with tumours affecting the visual pathway: Case reports // Doc. Ophthalmol. Springer, 2000. Vol. 101, № 2. P. 125-154.
Nitz A. et al. Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients // Oncol Lett, 2012. Vol. 5, № 1. P. 311-315.
Rodeberg D.A. et al. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: A report from the children’s oncology group // J. Clin. Oncol. J Clin Oncol, 2011. Vol. 29, № 10. P. 1304-1311.
Yadgarov M.Ya., Berikashvili L.B., Rakova E.S., Kachanov D.Yu., Likar Yu.N. Clinical and Translational Imaging (2024) https://doi.org/10.1007/s40336-024-00620-9.
Elmanzalawy, A., Vali, R., Chavhan, G. B., Gupta, A. A., Omarkhail, Y., Amirabadi, A., & Shammas, A. (2020). The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients. Pediatric radiology, 50(2), 252-260. https://doi.org/10.1007/s00247-019-04530-1
Soft Tissue and Bone Tumours WHO Classification of Tumours, 5th Edition, Volume 3 WHO Classification of Tumours Editorial Board 2020 ISBN-13
А.В. Панферова, Д.М. Коновалов, А.Е. Друй Молекулярно-генетическая гетерогенность рабдомиосарком у детей, Вопросы онкологии, 2024. Том 70, No 2УДК 616-006.36DOI 10.37469/0507-3758-2024-70-2-267-277
Страдомская Т.В. И др. Эффективность применения TRK-ингибитора энтректиниба у пациентов с экстракраниальными NTRK-перестроенными опухолями. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023;22(3):104-120.
Быстрова О.В. et al. Способы восстановления фертильности у онкологических больных // Практическая онкология. 2009. Vol. 10, № 4. P. 245-253.
Назаренко Т.А., Бурдули А.Г., Мартиросян Я.О., Джанашвили Л.Г. Криоконсервация репродуктивного материала у онкологических больных. Акушерство и гинекология. 2019; 9:40-9. https://dx.doi.org/10.18565/aig.2019.9.40-49
Borinstein S.C. et al. Consensus and controversies regarding the treatment of rhabdomyosarcoma // Pediatric Blood and Cancer. John Wiley and Sons Inc., 2018. Vol. 65, № 2.
Stevens M.C.G. Treatment for childhood rhabdomyosarcoma: The cost of cure // Lancet Oncology. Lancet Oncol, 2005. Vol. 6, № 2. P. 77-84.
Breneman J.C. et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the intergroup rhabdomyosarcoma study IV // J. Clin. Oncol. American Society of Clinical Oncology, 2003. Vol. 21, № 1. P. 78-84.
Puri D.R. et al. The challenging role of radiation therapy for very young children with rhabdomyosarcoma // Int. J. Radiat. Oncol. Biol. Phys. Int J Radiat Oncol Biol Phys, 2006. Vol. 65, № 4. P. 1177-1184.
Rodeberg D.A. et al. Surgical principles for children/adolescents with newly diagnosed rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group // Sarcoma. Hindawi Limited, 2002. Vol. 6, № 4. P. 111-122.
Dantonello T.M. et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. // J. Clin. Oncol. American Society of Clinical Oncology, 2009. Vol. 27, № 9. P. 1446-1455.
Koscielniak E. et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German cooperative soft tissue sarcoma study CWS-86 // J. Clin. Oncol. American Society of Clinical Oncology, 1999. Vol. 17, № 12. P. 3706-3719.
Bisogno G. et al. The IVADo regimen - A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: A pilot study on behalf of the European pediatric soft tissue sarcoma study group // Cancer. Cancer, 2005. Vol. 103, № 8. P. 1719-1724.
Minard-Colin V. et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE) // Eur. J. Cancer. Eur J Cancer, 2012. Vol. 48, № 15. P. 2409-2416.
Breneman J. et al. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: A report from the Children’S Oncology Group D9602 study // Int. J. Radiat. Oncol. Biol. Phys. Int J Radiat Oncol Biol Phys, 2012. Vol. 83, № 2. P. 720-726.
Chisholm J.C. et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study) // Eur. J. Cancer. Elsevier Ltd, 2017. Vol. 83. P. 177-184.
Klingebiel T. et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS-96 trial // Pediatr. Blood Cancer. Pediatr Blood Cancer, 2008. Vol. 50, № 4. P. 739-745.
Klingebiel T. et al. Treatment of Children With Relapsed Soft Tissue Sarcoma: Report of the German CESS/CWS REZ 91 Trial // Med. Pediatr. Oncol. Med Pediatr Oncol, 1998. Vol. 30, № 5.
Саркомы мягких тканей // Стандарты оказания специализированной помощи детям и подросткам с гематологическими и онкологическими заболеваниями. Медпрактика-М, Москва, 2009. P. 462-482.
Bisogno G. et al. Clinical practice guidelines for patients with rhabdomyosarcoma. https://siope.eu/media/documents/escp-rhabdomyosarcoma.pdf
Bisogno G. et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial // Lancet Oncol. Lancet Publishing Group, 2019. Vol. 20, № 11. P. 1566-1575.
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children"s Oncology Group Study. Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ. J Clin Oncol. 2017 Oct 1;35(28):3215-3221. doi: 10.1200/JCO.2017.73.4830).
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Lancet Oncol. 2020 Apr;21(4):531-540. doi: 10.1016/S1470-2045(19)30856-3.
Schoot RA, Chisholm JC, Casanova M, Minard-Colin V, Geoerger B, Cameron AL, Coppadoro B, Zanetti I, Orbach D, Kelsey A, Rogers T, Guizani C, Elze M, Ben-Arush M, McHugh K, van Rijn RR, Ferman S, Gallego S, Ferrari A, Jenney M, Bisogno G, Merks JHM. Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. J Clin Oncol. 2022 Nov 10;40(32):3730-3740. doi: 10.1200/JCO.21.02981.
Gleissner B, Chamberlain MC: Neoplastic meningitis. Lancet Neurol 5:443-52, 2006
Ferrari A, Brennan B, Casanova M, Corradini N, Berlanga P, Schoot RA, Ramirez-Villar GL, Safwat A, Guillen Burrieza G, Dall"Igna P, Alaggio R, Lyngsie Hjalgrim L, Gatz SA, Orbach D, van Noesel MM. Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer Manag Res. 2022 Sep 23;14:2885-2902. doi: 10.2147/CMAR.S368381.
Heinz AT, Ebinger M, Schönstein A, Fuchs J, Timmermann B, Seitz G, Vokuhl C, Münter MW, Pajtler KW, Stegmaier S, von Kalle T, Kratz CP, Rößler J, Ljungman G, Klingebiel T, Koscielniak E, Sparber-Sauer M; Cooperative Weichteilsarkom Studiengruppe (CWS). Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR). Pediatr Blood Cancer. 2023 Jul;70(7):e30363. doi: 10.1002/pbc.30363.
Ishida S, Yoshida K, Kaneko Y, Tanaka Y, Sasaki Y, Urano F, Umezawa A, Hata J, Fujinaga K. The genomic breakpoint and chimeric transcripts in the EWSR1-ETV4/E1AF gene fusion in Ewing sarcoma. Cytogenet Cell Genet. 1998;82(3-4):278-83. doi: 10.1159/000015119.
Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, Delattre O. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997 Mar 13;14(10):1159-64. doi: 10.1038/sj.onc.1200933.
Berg T, Kalsaas AH, Buechner J, Busund LT. Ewing sarcoma-peripheral neuroectodermal tumor of the kidney with a FUS-ERG fusion transcript. Cancer Genet Cytogenet. 2009 Oct;194(1):53-7. doi: 10.1016/j.cancergencyto.2009.06.002.
Hrzenjak A, Moinfar F, Tavassoli FA, Strohmeier B, Kremser ML, Zatloukal K, Denk H. JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecular analysis by reverse transcriptase-polymerase chain reaction optimized for paraffin-embedded tissue. J Mol Diagn. 2005 Aug;7(3):388-95. doi: 10.1016/S1525-1578(10)60568-5.
Drilon AD, Popat S, Bhuchar G, D"Adamo DR, Keohan ML, Fisher C, Antonescu CR, Singer S, Brennan MF, Judson I, Maki RG. Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer. 2008 Dec 15;113(12):3364-71. doi: 10.1002/cncr.23978.
Lewin J, Wieringa S, Collins M, Desai J, Orme L, Lingaratnam S, Thomas DM. Intra-patient dose escalation in Ewing"s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review. Clin Sarcoma Res. 2013 Dec 10;3(1):15. doi: 10.1186/2045-3329-3-15.
Trahair T, Gifford AJ, Fordham A, Mayoh C, Fadia M, Lukeis R, Wood AC, Valvi S, Walker RD, Blackburn J, Heyer EE, Mercer TR, Barbaric D, Marshall GM, MacKenzie KL. Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors. JCO Precis Oncol. 2019 May 16;3:PO.18.00297. doi: 10.1200/PO.18.00297.
Nakano K. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy. Jpn J Clin Oncol. 2023 Oct 4;53(10):885-892. doi: 10.1093/jjco/hyad074. PMID: 37394916.
Roy A, Gabani P, Davis EJ, Oppelt P, Merfeld E, Keedy VL, Zoberi I, Chrisinger JSA, Michalski JM, Van Tine B, Spraker MB. Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. Clin Transl Radiat Oncol. 2021 Jan 28;27:114-120. doi: 10.1016/j.ctro.2021.01.009. PMID: 33604458; PMCID: PMC7876514.
Apice G, Pizzolorusso A, Di Maio M, Grignani G, Gebbia V, Buonadonna A, De Chiara A, Fazioli F, De Palma G, Galizia D, Arcara C, Mozzillo N, Perrone F. Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. Sarcoma. 2016;2016:6862090. doi: 10.1155/2016/6862090. Epub 2016 Feb 25. PMID: 27019606; PMCID: PMC4785388.
Приказ МЗ РФ от 23.09.2020 №1008н "Об утверждении порядка обеспечения пациентов лечебным питанием"
Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Hütterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Mühlebach S, Oldervoll L, Ravasco P, Solheim TS, Strasser F, de van der Schueren M, Preiser JC, Bischoff SC. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021; 40(5):2898-2913. doi: 10.1016/j.clnu.2021.02.005
Вашура А.Ю. Нутритивная недостаточность, ее причины и пути коррекции у детей с опухолями ЦНС на этапе активной терапии и после ее окончания. Фарматека. 2019; 26 (10): 8-14
Парентеральное и энтеральное питание: национальное руководство / под ред. М.Ш. Хубутия, Т.С. Поповой, А.И. Салтанова. - М.: ГЭОТАР-Медиа, 2014. - 800с.
Mehta NM, Corkins MR, Lyman B, Malone A, Goday PS, Carney LN, Monczka JL, Plogsted SW, Schwenk WF; American Society for Parenteral and Enteral Nutrition Board of Directors. Defining pediatric malnutrition: a paradigm shift toward etiology-related definitions. JPEN J Parenter Enteral Nutr. 2013;37(4):460-81. doi: 10.1177/0148607113479972
Алымова Ю.А., Вашура А.Ю. Адекватная оценка нутритивного статуса в детской онкологии и гематологии - первый этап нутритивного сопровождения. Трудный пациент. 2019; Т. 17. № 8 (9). С. 54-59.
Martin L. et al. Diagnostic criteria for the classification of cancer-associated weight loss // J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, № 1. P. 90-99
Kondrup J. et al. ESPEN guidelines for nutrition screening 2002 // Clin. Nutr. Churchill Livingstone, 2003. Vol. 22, № 4. P. 415-421; Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11-48
Вашура АЮ, Кучер МА, Ковтун ТА, Алымова ЮA, Литвинов ДВ, Зубаровская ЛС, Кулагин АД. Роль и актуальность нутрициологического диагноза в онкопедиатрии. Медицинский Совет. 2023;(12):99-109
Yaprak D.S, Yalçın B., Pınar A.A., Büyükpamukçu M. Assessment of nutritional status in children with cancer: Significance of arm anthropometry and serum visceral proteins. Pediatr Blood Cancer. 2021;68(1):28752
Методические указания. Порядок проведения клинических исследований для оценки эффективности специализированной пищевой продукции диетического лечебного и диетического профилактического питания/ ФГБУН "ФИЦ питания и биотехнологии", Роспотребнадзор, Минздрав России, ФГБУН "ФНЦГ им. Ф.Ф.Эрисмана" Роспотребнадзора. - Москва. - 2023. - 28с.
Методическое руководство. Стандарты лечебного питания/ ФГБУН "ФИЦ питания и биотехнологии". - Москва. - 2017. - 338с.
Вашура А.Ю., Пятаева А.А., Карелин А.Ф. Питание и нутритивная поддержка детей со злокачественными новообразованиями после завершения лечения: основные аспекты. Вопросы детской диетологии. 2022; 20(6): 64-70
Rayar M., Webber C.E., Nayiager T., Sala A., Barr R.D. Sarcopenia in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2013;35:98-102; Pietila S., Makipernaa A., Sievanen H., Koivisto A.M., Wigren T., Lenko H.L. Obesity and metabolic changes are common in young childhood brain tumor survivors. Pediatr Blood Cancer. 2009;52:853-9
Joosten K, Embleton N, Yan W, Senterre T; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Energy. Clin Nutr. 2018;37(6 Pt B):2309-2314. doi:10.1016/j.clnu.2018.06.944
Особенности нутриционной поддержки больных в педиатрии. В кн.: Клиническое питание больных в интенсивной медицине: практическое руководство /под ред. Луфта В. М., Багненко С. Ф., издание второе, дополненное. СПб.: Арт-Экспресс, 2013-460.
Парентеральное и энтеральное питание детей. Практические рекомендации. Под ред. Ерпулевой Ю.В., Чубаровой А.И., Чугуновой Ю.Л. ГЭОТАР-Медиа, 2016г. 304с.; Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11-48
Современные рекомендации по питанию детей / под ред. Проф. Ю.Г. Мухиной, проф. И.Я. Коня. - М.: ИД "МЕДПРАКТИКА-М", 2010,568с.
Ерпулёва Ю. В. Парентеральное питание у детей Российский вестник детской хирургии, анестезиологии и реаниматологии. 2018; 8(1):49-56
Viani K., Trehan A., Manzoli B., Schoeman J. Assessment of nutritional status in children with cancer: A narrative review. Pediatr Blood Cancer. 2020;67 Suppl 3:e28211. https://doi: 10.1002/pbc.2821
Koletzko B., Goulet O., Hunt J., Krohn K., Shamir R. for the Parenteral Nutrition Guidelines Working Group. Guidelines on Paediatric Parenteral nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paeditric Research (ESPR). J. Pediatr. Gastroenterol.Nutr. 2005; 41: Suppl.2: S1‑S87. DOI: 10.1097/01. mpg.0000181841.07090.f4
Nickel B, Gorski L, Kleidon T, Kyes A, DeVries M, Keogh S, Meyer B, Sarver MJ, Crickman R, Ong J, Clare S, Hagle ME. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024 Jan-Feb 01;47(1S Suppl 1):S1-S285. doi: 10.1097/NAN.0000000000000532. PMID: 38211609.
Венозный катетер. Использование, уход, контроль, осложнения: учебное пособие / Сацук А.В., Солопова Г.Г., Щукин В.В., Литвинов Д.В., Пименова О.В. Климова Н.А., Щемелинская Ю.Л., Масчан А.А, Новичкова Г.А. - М. АО "Информатика", 2023. - 152 с.: ил. ISBN 978-5-6049537-2-3.
Occlusion Management Guideline (OMG) [Electronic resource]. URL: https://cvaa.info/en/publications/occlusion-management-guideline-omg
Pittiruti M, Van Boxtel T, Scoppettuolo G, Carr P, Konstantinou E, Ortiz Miluy G, Lamperti M, Goossens GA, Simcock L, Dupont C, Inwood S, Bertoglio S, Nicholson J, Pinelli F, Pepe G. European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): A WoCoVA project. J Vasc Access. 2023 Jan;24(1):165-182. doi: 10.1177/11297298211023274. Epub 2021 Jun 4. PMID: 34088239.
Cellini M, Bergadano A, Crocoli A, Badino C, Carraro F, Sidro L, Botta D, Pancaldi A, Rossetti F, Pitta F, Cesaro S. Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease. J Vasc Access. 2020 Nov 10:1129729820969309. doi: 10.1177/1129729820969309. Epub ahead of print. PMID: 33169648.
Murgo M, Spencer T, Breeding J, Alexandrou E, Baliotis B, Hallett T, Guihermino M, Martinich I, Frogley M, Denham J, Whyte R, Ray-Barruel B and Richard C (2014) Central Venous Access Device - Post Insertion Management. Agency for Clinical Innovation NSW Health Australia 978-1-74187-953-7.
Rosenthal, Victor & Kanj, Souha & Desse, Javier & Alkhawaja, Safaa & Cimerman, Sergio & Rodriguez-Morales, Alfonso & El Kholy, Amani & Opintan, Japheth & Avortri, Gertrude & Singh, Sanjeev & Mehta, Yatin & Mitsuda, Toshihiro & Al-Abdely, Hail & Kamarulzaman, Adeeba & Mota, Maria & Trejo, Roxana & Ider, Bat-Erdene & Enciso, Hernan & Collantes, Sofia & Leblebicioglu, Hakan. (2017). Bundle of the International Nosocomial Infection Control Consortium (INICC) to Prevent Central and Peripheral Line-Related Bloodstream Infections.
"Эпидемиология и профилактика катетер-ассоциированных инфекций кровотока и уход за центральным венозным катетером": Методические рекомендации/ Сост.: коллектив авторов Брико Н.И., Биккулова Д.Ш., Брусина Е.Б., Ершова О.Н., Животнева И.В., Заболотский Д.В., Иванова О.А., Квашнина Д.В., Ковалишена О.В., Кузьков В.В., Кулабухов В.В., Пивкина А.И., Пименова О.В., Сацук А.В., Солопова Г.Г., Суранова Т.Г., Щукин В.В. - Москва. 2022 г.
WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. Geneva: World Health Organization; 2009. PMID: 23805438.
Приказ Минздрава России от 20.10.2020 № 1134н "Об утверждении порядка медицинского обследования реципиента, проведения проб на индивидуальную совместимость, включая биологическую пробу, при трансфузии донорской крови и (или) ее компонентов" (Зарегистрировано в Минюсте России 12.11.2020 N 60868).
National Healthcare Safety Network (NHSN) (National Healthcare Safety Network (NHSN)/ Patient Safety Component Manual, Chapter 4. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection), 2024 г.).
Patel P. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. // Patel P, Robinson PD, Wahib N [et al] // Support Care Cancer. 2022 Nov;30(11):8855-8869. doi: 10.1007/s00520-022-07287-w
Hesketh, P.J. Antiemetics: ASCO Guideline Update / P.J. Hesketh, M.G. Kris, E. Basch [et al.] // J Clin Oncol. - 2020. - JCO2001296. - doi:10.1200/JCO.20.01296.] и COG (Children’s Oncology Group)
Ramavath, D.N. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial / D.N. Ramavath, V. Sreenivas, S. Vishwajeet [et al.] // Journal of Clinical Oncology. - 2020. - Vol. 38 (32). - P. 3785-3793. - doi: 10.1200/JCO.20.00871;
Жуков, Н.В. Эффективность и безопасность малых доз оланзапина в профилактике тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию. Промежуточные результаты рандомизированного исследования / Н.В. Жуков, Л.Л. Рабаева, Д.В. Литвинов // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. - 2022. − №4. - С. 70-82. doi: 10.24287/1726-1708-2022-21-4-70-82
Owais Mohammed. Efficacy, safety and cost effectiveness of reduced-dose olanzapine versus aprepitant as a part of triple-antiemetic therapy in the prevention of chemotherapy induced nausea and vomiting / Owais Mohammed, Narender kumar Thota // Journal of Clinical Oncology - 2022. Vol. 40 (16) - doi:10.1200/JCO.2022.40.16_suppl.e24078;
Rudolph M.Navari. Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602). / Rudolph M. Navari, Jennifer Le-Rademacher, Fabrice Smieliauskas [et al] // - 2022. Vol. 40 (16) - https://doi.org/10.1200/JCO.2022.40.16_suppl.12107
Patil, V. Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children / V. Patil, H. Prasada, K. Prasad [et al.] // J Community Support Oncol. - 2015. - Vol. 13 (6). - P. 209-213. - doi: 10.12788/jcso.0139;
Chaudhary, N.K. Palonosetron is a Better Choice Compared with Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results from a Randomized Control Trial / N.K. Chaudhary, R.R. John, D. Boddu [et al.] // J Pediatr Hematol Oncol. - 2019. - Vol. 41 (4). - P. 294-297. - doi: 10.1097/MPH.0000000000001357
Flank, J. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children with Cancer / J. Flank, P.D. Robinson, M. Holdsworth [et al.] // Pediatr Blood Cancer. - 2016. - Vol. 63 (7). - P. 1144-1151. - doi:10.1002/pbc.25955
Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014 Aug;4(8):889-95. doi: 10.1158/2159-8290.CD-14-0377. Epub 2014 May 29. PMID: 24875859; PMCID: PMC4125481.
Palassini E, Baldi GG, Sulfaro S, et. al. Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group. Cancer Treat Rev. 2024 May;126:102722. doi: 10.1016/j.ctrv.2024.102722. Epub 2024 Mar 30. PMID: 3860405
Fazel M, Dufresne A, Vanacker H, Waissi W, Blay JY, Brahmi M. Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond. Cancers (Basel). 2023 Mar 7;15(6):1643. doi: 10.3390/cancers15061643. PMID: 36980528; PMCID: PMC10046205.2.
Ferrari A, Merks JHM, Chisholm JC, Orbach D, Brennan B, Gallego S, van Noesel MM, McHugh K, van Rijn RR, Gaze MN, Martelli H, Bergeron C, Corradini N, Minard-Colin V, Bisogno G, Geoerger B, Caron HN, De Salvo GL, Casanova M. Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. Eur J Cancer. 2020 May;130:72-80. doi: 10.1016/j.ejca.2020.01.029. Epub 2020 Mar 13. PMID: 32179448.
Bercovitz RS., Josephson CD. Transfusion considerations in pediatric hematology and oncology patients. Hematol Oncol Clin North Am. 2016; 30(3): 695-709. doi: 10.106/j.hoc.2016.01.010.
Steiner ME, Zantek ND, Stanworth SJ, Parker RI, et al. Recommendations on RBC Transfusion Support in Children With Hematologic and Oncologic Diagnoses From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med. 2018 Sep;19(9S Suppl 1): 149-156.
Shah N., Andrews J., Goodnough LT. Transfusions for anemia in adult and pediatric patients with malignancies. Blood Reviews. 2015; 29(5): 291-299. doi: 10.106/j.blre.2015.02.001
Nellis ME, Goel R, Karam O. Transfusion Management in Pediatric Oncology Patients. Hematol Oncol Clin North Am. 2019; 33(5): 903-913. doi: 10.1016/j.hoc.2019.05.011.
World Health Organization. (‎2021)‎. Educational modules on clinical use of blood. https://www.who.int/publications/i/item/9789240033733
Долгов ВВ., Свирин ПВ. Лабораторная диагностика нарушений гемостаза. Москва: Триада, 2005 - с150. ISBN 5-94789-114-x.
Кречетова А.В. Нарушение гемостаза при сепсисе у онкогематологических больных c миелотоксическим агранулоцитозом: автореф. Дис канд мед. наук. М.: Гематологический научный центр; 2011
Kozek-langenecker S.A., Afshari A., Albaladejo P., et al. Management of severe perioperative bleeding Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30: 270-382. DOI: 10.1097/ EJA.0b013e32835f4d5.
9O"Shaughnessy D., Atterbury C., Bolton Maggs P., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Hematol. 2004; 126(1): 11-28. DOI: 10.1111/j. 1365-2141,2004.04972.x.
Галстян Г.М., Гапонова Т.В., Жибурт Е.Б., Балашова Е.Н., Берковский А.Л., Быстрых О.А., Купряшов А.А., Оловникова Н.И., Ошоров А.В., Рыбка М.М., Троицкая В.В., Буланов А.Ю., Журавель С.В., Лубнин А.Ю., Мазурок В.А., Недомолкин С.В., Певцов Д.Э., Рогачевский О.В., Салимов Э.Л., Трахтман П.Е., Чжао А.В., Шерстнев Ф.С., Савченко В.Г. Клиническое использование криопреципитата. Гематология и трансфузиология. 2020; 65(1): 87-114. doi.org/10.35754/0234-5730-2020-65-1-87-114
Зацаринная О.С., Топорков М.А., Андреева Н.А., Телешова М.В., Уталиева Д.Т., Страдомская Т.В., Щербаков А.П., Грачев Н.С., Большаков Н.А., Сидоров И.В., Коновалов Д.М., Нечеснюк А.В., Шаманская Т.В., Жуков Н.В., Качанов Д.Ю. Ангиосаркома у детей: опыт нмиц дгои им. Дмитрия рогачева и обзор литературы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023. Т. 22. № 4. С. 23-36.
Trahair T, Gifford AJ, Fordham A, Mayoh C, Fadia M, Lukeis R, Wood AC, Valvi S, Walker RD, Blackburn J, Heyer EE, Mercer TR, Barbaric D, Marshall GM, MacKenzie KL. Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors. JCO Precis Oncol. 2019 May 16;3:PO.18.00297. doi: 10.1200/PO.18.00297
Langford P, Chrisp P. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2010 Oct 21;5:77-90. doi: 10.2147/ce.s6012. PMID: 21042544; PMCID: PMC2963924
Patel P, Olteanu A, Cabral S, Santesso N, Robinson PD, Dupuis LL. Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review. Pediatr Blood Cancer. 2020 Dec;67(12):e28716. doi: 10.1002/pbc.28716. Epub 2020 Sep 24. PMID: 32970373.
Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P, Orsey A, Portwine C, Freedman J, Madden JR, Phillips R, Sung L, Dupuis LL. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26542. Epub 2017 Apr 28. PMID: 28453189.